Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
M.D. Anderson Cancer Center |
---|---|
Information provided by: | M.D. Anderson Cancer Center |
ClinicalTrials.gov Identifier: | NCT00554268 |
The Primary Objectives of this study are:
The Secondary Objectives of this study are:
Condition | Intervention | Phase |
---|---|---|
Solid Tumors |
Drug: PBI-05204 |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | An Open Label Phase I Trial of PBI-05204 in Advanced Cancer Patients |
Estimated Enrollment: | 40 |
Study Start Date: | October 2007 |
Estimated Primary Completion Date: | November 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental
PBI-05204
|
Drug: PBI-05204
Starting Dose = 0.0083 mg/kg/day PO x 3 Weeks Per Cycle
|
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: David S. Hong, MD | 713-563-5844 |
United States, Texas | |
U.T.M.D. Anderson Cancer Center | Recruiting |
Houston, Texas, United States, 77030 | |
Principal Investigator: David S. Hong, MD |
Principal Investigator: | David S. Hong, MD | U.T.M.D. Anderson Cancer Center |
Responsible Party: | U.T.M.D. Anderson Cancer Center ( David S. Hong, MD/Assistant Professor ) |
Study ID Numbers: | 2007-0375 |
Study First Received: | November 2, 2007 |
Last Updated: | January 5, 2009 |
ClinicalTrials.gov Identifier: | NCT00554268 |
Health Authority: | United States: Institutional Review Board |
Advanced Cancers Solid Tumors PBI-05204 |